Sei Investments Co. Sells 7,231 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Sei Investments Co. decreased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 32.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 14,927 shares of the company’s stock after selling 7,231 shares during the period. Sei Investments Co.’s holdings in Pacira BioSciences were worth $281,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Caitlin John LLC grew its position in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after purchasing an additional 918 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Pacira BioSciences in the 4th quarter valued at approximately $190,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

PCRX has been the topic of a number of research reports. Barclays boosted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. HC Wainwright boosted their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Pacira BioSciences in a research report on Tuesday. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price target for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences presently has a consensus rating of “Hold” and an average price target of $26.67.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $23.69 on Friday. The company has a market cap of $1.10 billion, a P/E ratio of -11.67 and a beta of 0.71. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The business has a 50-day moving average price of $24.78 and a two-hundred day moving average price of $20.74. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.